世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のトラベルワクチン市場 2018-2022年

Global Travel Vaccines Market 2018-2022

IRTNTR22195

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年12月US$2,500
シングルユーザライセンス
118

サマリー

この調査レポートは世界のトラベルワクチン市場を分析・予測したTechNavioの市場調査報告書です。

Description

About this market
Increased incidence of travel-related diseases is expected to drive the market growth. Traveling is often associated with higher health risks especially regarding infectious diseases. Thus, the rising incidence of travel related diseases will lead to more investments in the global travel vaccines market for the development of more effective vaccines. Technavio’s analysts have predicted that the travel vaccines market will register a CAGR of almost 10% by 2022.
Market Overview
Increase in global travel and migration
With the rise in traveling over the past few years has resulted in the spread of pathogens and disease-causing vectors worldwide. The increase in travel and migration offers huge opportunities to the manufacturers to invest in the R&D of new and more effective vaccines.
High cost of travel vaccinations
Travel clinics offer vaccinations at a slightly higher price and new vaccines are usually more expensive.
For the detailed list of factors that will drive and challenge the growth of the travel vaccines market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Sanofi and Valneva the competitive environment is quite intense. Factors such as the increased incidence of travel-related diseases and the increase in global travel and migration, will provide considerable growth opportunities to travel vaccines manufactures. GlaxoSmithKline, Pfizer, Sanofi, and Valneva are some of the major companies covered in this report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
- Pipeline analysis
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: MARKET SEGMENTATION BY TARGET DISEASE FOR IMMUNIZATION
- Segmentation by target disease for immunization
- Comparison by target disease for immunization
- Influenza - Market size and forecast 2017-2022
- Diphtheria - Market size and forecast 2017-2022
- Others - Market size and forecast 2017-2022
- Hepatitis - Market size and forecast 2017-2022
- Typhoid - Market size and forecast 2017-2022
- Polio - Market size and forecast 2017-2022
- Yellow fever - Market size and forecast 2017-2022
- Market opportunity by target disease
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity by region
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Changes in the demographic profile of travelers globally
- Increased incidence of travel-related diseases
- Initiatives by governments and other organizations to ensure travel safety
- Evolving epidemiological patterns of infectious diseases in different countries
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- GlaxoSmithKline
- Pfizer
- Sanofi
- Valneva
PART 16: APPENDIX
- List of abbreviations

Exhibit 01: Parent market
Exhibit 02: Global human vaccines market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline Vaccines Under Phase III Development
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Target disease for immunization - Market share 2017-2022 (%)
Exhibit 20: Comparison by target disease for immunization
Exhibit 21: Influenza - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Influenza - Year-over-year growth 2018-2022 (%)
Exhibit 23: Diphtheria - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Diphtheria - Year-over-year growth 2018-2022 (%)
Exhibit 25: Others - Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Others - Year-over-year growth 2018-2022 (%)
Exhibit 27: Hepatitis - Market size and forecast 2017-2022 ($ mn)
Exhibit 28: Hepatitis - Year-over-year growth 2018-2022 (%)
Exhibit 29: Typhoid - Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Typhoid - Year-over-year growth 2018-2022 (%)
Exhibit 31: Polio - Market size and forecast 2017-2022 ($ mn)
Exhibit 32: Polio - Year-over-year growth 2018-2022 (%)
Exhibit 33: Yellow fever - Market size and forecast 2017-2022 ($ mn)
Exhibit 34: Yellow fever - Year-over-year growth 2018-2022 (%)
Exhibit 35: Market opportunity by target disease for immunization
Exhibit 36: Customer landscape
Exhibit 37: Global - Market share by geography 2017-2022 (%)
Exhibit 38: Regional comparison
Exhibit 39: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 40: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 41: Top 3 countries in Americas
Exhibit 42: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 43: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 44: Top 3 countries in EMEA
Exhibit 45: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 46: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 47: Top 3 countries in APAC
Exhibit 48: Market opportunity
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: GlaxoSmithKline - Overview
Exhibit 55: GlaxoSmithKline - Business segments
Exhibit 56: GlaxoSmithKline - Organizational developments
Exhibit 57: GlaxoSmithKline - Geographic focus
Exhibit 58: GlaxoSmithKline - Segment focus
Exhibit 59: GlaxoSmithKline - Key offerings
Exhibit 60: Pfizer - Overview
Exhibit 61: Pfizer - Business segments
Exhibit 62: Pfizer - Organizational developments
Exhibit 63: Pfizer - Geographic focus
Exhibit 64: Pfizer - Segment focus
Exhibit 65: Pfizer - Key offerings
Exhibit 66: Sanofi - Overview
Exhibit 67: Sanofi - Business segments
Exhibit 68: Sanofi - Organizational developments
Exhibit 69: Sanofi - Geographic focus
Exhibit 70: Sanofi - Segment focus
Exhibit 71: Sanofi - Key offerings
Exhibit 72: Valneva - Overview
Exhibit 73: Valneva? Business segments
Exhibit 74: Valneva - Organizational developments
Exhibit 75: Valneva - Geographic focus
Exhibit 76: Valneva - Key offerings


?

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る